Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BACTEK-R (MV130) in Mild COVID-19 Pneumonia
NCT04363814Phase 3Unknown
- Sponsor
- Inmunotek
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of MV130 in COVID-19 pneumonia (2 arms), sponsored by Inmunotek. Primary endpoints: Clinical recovery at 2 weeks and Clinical worsening at 2 weeks. Status: unknown.
02
Drugs
MV130
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04363814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04363814.